Form 4: ProMIS Neurosciences Insider Jeremy Sclar Acquires Shares and Warrants in Private Placement

Jeremy M. Sclar, a director and 10% owner of ProMIS Neurosciences Inc., acquired common shares and warrants through a private placement and conversion of preferred shares on July 31, 2024.

Summary

• On July 31, 2024, Jeremy M. Sclar acquired 697,674 common shares and various tranches of warrants through a private placement at a price of $2.15 per unit.
• The private placement included Tranche A, Tranche B, and Tranche C warrants, each exercisable for one common share.
• Sclar also acquired 150,000 common shares through the conversion of Series 2 Preferred Shares following a qualified equity financing exceeding $14 million.
• The transactions were conducted through the Jeremy M. Sclar 2012 Irrevocable Family Trust and Crocker Mountain LLC, entities in which Sclar has indirect beneficial ownership.
• Following these transactions, Sclar directly owns 65,000 common shares and indirectly owns a significant number of common shares and warrants through the aforementioned entities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects standard insider trading activity related to a previously announced private placement. The insider's participation is a positive signal, but the overall impact is likely already priced into the stock.

Positives

• Insider participation in a private placement can signal confidence in the company's future prospects.
• The conversion of preferred shares to common shares simplifies the capital structure.

Risks

• The exercise of warrants could lead to dilution of existing shareholders' equity.
• The timing of warrant exercises is dependent on shareholder approval and data releases related to PMN310.

Future Outlook

The timing of warrant exercises depends on shareholder approval and the release of data from PMN310 trials.

Industry Context

Insider transactions are closely monitored as indicators of management's confidence in the company's prospects, particularly in the biotechnology sector where clinical trial results and regulatory approvals are critical.

Comparison to Industry Standards

• Comparing this transaction to similar insider purchases in comparable biotech firms would require analyzing the size of the purchase relative to the insider's existing holdings and the company's market capitalization.
• For example, if a CEO of a similarly sized biotech company purchased a comparable amount of shares after positive clinical trial data, it would be viewed more favorably than a purchase before a critical data release.
• Companies like Biogen or Ionis Pharmaceuticals often see insider activity around key clinical milestones, providing a benchmark for evaluating the significance of this transaction.

Stakeholder Impact

• Shareholders may experience dilution if warrants are exercised.
• The private placement provides additional capital to the company, potentially benefiting stakeholders through the advancement of research and development.

Next Steps

• Shareholder approval may be required for the issuance of shares upon exercise of Tranche A and B warrants.
• The expiration of Tranche A and B warrants is tied to the release of 6-month and 12-month data from PMN310 trials, respectively.

Key Dates